Difference between revisions of "Estrogen receptor"
Jump to navigation
Jump to search
| Line 6: | Line 6: | ||
==Positive== | ==Positive== | ||
*Normal breast - usually patchy staining. | |||
*[[Florid epithelial hyperplasia of the usual type]] - usually patchy staining.<ref name=Ref_BP276>{{Ref BP|276}}</ref> | |||
*[[Breast carcinoma]] - most. | *[[Breast carcinoma]] - most. | ||
**[[Ductal carcinoma in situ]] - most. | **[[Ductal carcinoma in situ]] - most, usually diffuse.<ref name=Ref_BP276>{{Ref BP|276}}</ref> | ||
**[[Invasive lobular carcinoma]] - all. | **[[Invasive lobular carcinoma]] - all. | ||
**[[Invasive ductal carcinoma of the breast]] - most. | **[[Invasive ductal carcinoma of the breast]] - most. | ||
Revision as of 20:39, 23 June 2016
Estrogen receptor, abbreviated ER, is a common immunostain.
General
- Nuclear stain - like most other "p" stains.
- In the context of breast pathology it is a class II IHC test, as it is used for treatment decisions by itself.[1]
Positive
- Normal breast - usually patchy staining.
- Florid epithelial hyperplasia of the usual type - usually patchy staining.[2]
- Breast carcinoma - most.
- Ductal carcinoma in situ - most, usually diffuse.[2]
- Invasive lobular carcinoma - all.
- Invasive ductal carcinoma of the breast - most.
- Endometrial carcinomas.
Occasionally positive
- Lung adenocarcinoma - dependent on the ER subunit target - ERα ~1%, ERβ ~79%.[3]
Negative
See also
References
- ↑ Torlakovic, EE.; Riddell, R.; Banerjee, D.; El-Zimaity, H.; Pilavdzic, D.; Dawe, P.; Magliocco, A.; Barnes, P. et al. (Mar 2010). "Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee/Immunohistochemistry: best practice recommendations for standardization of immunohistochemistry tests.". Am J Clin Pathol 133 (3): 354-65. doi:10.1309/AJCPDYZ1XMF4HJWK. PMID 20154273.
- ↑ 2.0 2.1 O'Malley, Frances P.; Pinder, Sarah E. (2006). Breast Pathology: A Volume in Foundations in Diagnostic Pathology series (1st ed.). Churchill Livingstone. pp. 276. ISBN 978-0443066801.
- ↑ Tanaka, K.; Shimizu, K.; Kakegawa, S.; Ohtaki, Y.; Nagashima, T.; Kaira, K.; Horiguchi, J.; Oyama, T. et al. (2016). "Prognostic significance of aromatase and estrogen receptor beta expression in EGFR wild-type lung adenocarcinoma.". Am J Transl Res 8 (1): 81-97. PMID 27069542.
- ↑ Hu, WW.; Tao, JH.; Li, GM.; Xu, X.; Yang, XM. (Mar 2010). "[Value of ER, VIM, CEA and p16 detection in the diagnosis and differential diagnosis of primary endocervical and endometrial adenocarcinomas].". Nan Fang Yi Ke Da Xue Xue Bao 30 (3): 526-8, 531. PMID 20335127.